UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

A Computational Model of the Human Left-Ventricular Epicardial Myocyte

Biophysical journal, 2004-09, Vol.87 (3), p.1507-1525

2004

Link zum Volltext

Verfügbarkeit prüfen

Competitiveness, entrepreneurship, and economic performance: Evidence from factor-, efficiency-, and innovation-driven countries

Ekonomski anali, 2019, Vol.64 (221), p.33-64

2019

Link zum Volltext

Verfügbarkeit prüfen

CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

Frontiers in physiology, 2017-11, Vol.8, p.894-894

2017

Link zum Volltext

Verfügbarkeit prüfen

Modification of polyacrylonitrile TFC-FO membrane by biowaste-derived hydrophilic N-doped carbon quantum dots for enhanced water desalination performance

Desalination, 2023-11, Vol.565, p.116888, Article 116888

2023

Link zum Volltext

Verfügbarkeit prüfen

A Decision Support System for Evaluating Success Factors of Projects in the Oil and Gas Industry

Mathematical problems in engineering, 2022-11, Vol.2022, p.1-18

2022

Link zum Volltext

Verfügbarkeit prüfen

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

Pharmacology research & perspectives, 2015-12, Vol.3 (6), p.e00198-n/a

2015

Link zum Volltext

Verfügbarkeit prüfen

The anticancer effects of supinoxin (RX-5902) in pancreatic carcinoma

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.238-238

2016

Link zum Volltext

Verfügbarkeit prüfen

The anticancer effects of supinoxin (RX-5902) in renal cell cancer

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.524-524

2016

Link zum Volltext

Verfügbarkeit prüfen

Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.550-550

2016

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I study of RX-5902: An orally bioavailable inhibitor of phosphorylated P68, targeting solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2554-2554

2016

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 1 study of single agent RX-3117: An oral antimetabolite nucleoside to treat solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2555-2555

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT114: Phase Ib/II Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma - Phase Ib results

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT114-CT114

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT114: Phase IbII Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma - Phase Ib results

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT114-CT114

2016

Link zum Volltext

Verfügbarkeit prüfen

Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2559-2559

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1790: Evaluation of UCK2 protein expression as a potential predictive biomarker of RX-3117

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1790-1790

2017

Link zum Volltext

Verfügbarkeit prüfen

Transmural distribution of three-dimensional systolic strains in stunned myocardium

Circulation (New York, N.Y.), 2001-07, Vol.104 (3), p.336-341

2001

Link zum Volltext

Verfügbarkeit prüfen

A PHASE I/IIA FIRST IN MAN SAFETY AND TOLERABILITY STUDY OF A NOVEL HNO DONOR, CXL-1020, IN PATIENTS WITH STABLE CONGESTIVE HEART FAILURE

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E299-E299

2011

Link zum Volltext

Verfügbarkeit prüfen

“Are We There Yet?!”: Cardiac Channelopathy and Our Journey Toward Computational Medicine

Circulation research, 2002-05, Vol.90 (8), p.842-843

Mazhari, Reza

2002

Link zum Volltext

Verfügbarkeit prüfen

CXL-1020, A NOVEL HNO DONOR, DECREASES MYOCARDIAL LOADING AND ENHANCES LOAD-INDEPENDENT LUSITROPY AND INOTROPY VIA A ?-AR/ACE INDEPENDENT MECHANISM

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E326-E326

2011

Link zum Volltext

Verfügbarkeit prüfen

Molecular Interactions Between Two Long-QT Syndrome Gene Products, HERG and KCNE2, Rationalized by In Vitro and In Silico Analysis

Circulation research, 2001-07, Vol.89 (1), p.33-38

2001

Link zum Volltext

Verfügbarkeit prüfen

Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval

The Journal of clinical investigation, 2002-04, Vol.109 (8), p.1083-1090

2002

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Infusion of the Novel HNO Donor, CXL-1020, Improves Cardiac Mechano-Energetics: Comparison With Sodium Nitroprusside

Journal of cardiac failure, 2010, Vol.16 (8), p.S72-S73

2010

Link zum Volltext

Verfügbarkeit prüfen

Assessing load-independent inotropy/lusitropy in vivo in the setting of altered myocardial loading: Closed chest pressure volume analysis in anesthetized rats

Journal of pharmacological and toxicological methods, 2011-07, Vol.64 (1), p.e28-e29

2011

Link zum Volltext

Verfügbarkeit prüfen

Nitroxyl (HNO): A novel approach for the acute treatment of heart failure

Circulation. Heart failure, 2013-11, Vol.6 (6), p.1250-1258

2013

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Infusion of Novel HNO Donor, CXL-1020, Improves Left Ventricular Contractile Function in Normal and Failing Dogs

Journal of cardiac failure, 2009, Vol.15 (6), p.S75-S75

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(65)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A Computational Model of the Human Left-Ventricular Epicardial Myocyte

Competitiveness, entrepreneurship, and economic performance: Evidence from factor-, efficiency-, and innovation-driven countries

CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

Modification of polyacrylonitrile TFC-FO membrane by biowaste-derived hydrophilic N-doped carbon quantum dots for enhanced water desalination performance

A Decision Support System for Evaluating Success Factors of Projects in the Oil and Gas Industry

Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

The anticancer effects of supinoxin (RX-5902) in pancreatic carcinoma

The anticancer effects of supinoxin (RX-5902) in renal cell cancer

Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data

Results of a phase I study of RX-5902: An orally bioavailable inhibitor of phosphorylated P68, targeting solid tumors

Results of a phase 1 study of single agent RX-3117: An oral antimetabolite nucleoside to treat solid tumors

Abstract CT114: Phase Ib/II Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma - Phase Ib results

Abstract CT114: Phase IbII Study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma - Phase Ib results

Results from a phase 1b/2 study of RX-0201, a novel AKT-1 antisense, combined with everolimus to treat metastatic clear cell renal carcinoma

Abstract 1790: Evaluation of UCK2 protein expression as a potential predictive biomarker of RX-3117

Transmural distribution of three-dimensional systolic strains in stunned myocardium

A PHASE I/IIA FIRST IN MAN SAFETY AND TOLERABILITY STUDY OF A NOVEL HNO DONOR, CXL-1020, IN PATIENTS WITH STABLE CONGESTIVE HEART FAILURE

“Are We There Yet?!”: Cardiac Channelopathy and Our Journey Toward Computational Medicine

CXL-1020, A NOVEL HNO DONOR, DECREASES MYOCARDIAL LOADING AND ENHANCES LOAD-INDEPENDENT LUSITROPY AND INOTROPY VIA A ?-AR/ACE INDEPENDENT MECHANISM

Molecular Interactions Between Two Long-QT Syndrome Gene Products, HERG and KCNE2, Rationalized by In Vitro and In Silico Analysis

Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval

Intravenous Infusion of the Novel HNO Donor, CXL-1020, Improves Cardiac Mechano-Energetics: Comparison With Sodium Nitroprusside

Assessing load-independent inotropy/lusitropy in vivo in the setting of altered myocardial loading: Closed chest pressure volume analysis in anesthetized rats

Nitroxyl (HNO): A novel approach for the acute treatment of heart failure

Intravenous Infusion of Novel HNO Donor, CXL-1020, Improves Left Ventricular Contractile Function in Normal and Failing Dogs

Suchergebnisse filtern